Last reviewed · How we verify
Cyclophosphamide (CYC)
Cyclophosphamide is an alkylating agent that cross-links DNA strands, preventing cell division and causing cell death in rapidly dividing cells.
Cyclophosphamide is an alkylating agent that cross-links DNA strands, preventing cell division and causing cell death in rapidly dividing cells. Used for Lymphomas (Hodgkin and non-Hodgkin), Breast cancer, Ovarian cancer.
At a glance
| Generic name | Cyclophosphamide (CYC) |
|---|---|
| Sponsor | Hansa Biopharma AB |
| Drug class | Alkylating agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology, Immunology |
| Phase | FDA-approved |
Mechanism of action
Cyclophosphamide is a nitrogen mustard derivative that acts as a prodrug, requiring hepatic activation to form active metabolites. These metabolites bind to DNA and form inter- and intra-strand cross-links, disrupting DNA replication and transcription. It is used both as a cytotoxic chemotherapy agent and as an immunosuppressant at lower doses due to its ability to deplete lymphocytes.
Approved indications
- Lymphomas (Hodgkin and non-Hodgkin)
- Breast cancer
- Ovarian cancer
- Lung cancer
- Leukemias
- Multiple myeloma
- Severe rheumatoid arthritis (immunosuppressive use)
- Systemic lupus erythematosus (immunosuppressive use)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Alopecia
- Hemorrhagic cystitis
- Infertility (gonadal dysfunction)
- Secondary malignancies
- Immunosuppression and infection risk
- Cardiotoxicity (at high doses)
Key clinical trials
- Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
- Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
- Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes (NA)
- A Study With Imlifidase in Anti-GBM Disease (PHASE3)
- CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 (PHASE1)
- Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease (PHASE4)
- A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis (PHASE1)
- Two Anti-CD20 Regimens for Fibrillary Glomerulonephritis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclophosphamide (CYC) CI brief — competitive landscape report
- Cyclophosphamide (CYC) updates RSS · CI watch RSS
- Hansa Biopharma AB portfolio CI